Hypertension treatment in African Americans: Physiology is less important than sociology

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 9, 2004, Pages 735-743

  Martins, David ^a   Norris, Keith ^a,b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b Clinical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PRAVASTATIN; RAMIPRIL; THIAZIDE DIURETIC AGENT; TICLOPIDINE;

AFRICAN AMERICAN; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CULTURAL FACTOR; DIET THERAPY; DRUG EFFICACY; DRUG RESPONSE; ECONOMIC ASPECT; ETHNIC DIFFERENCE; HEART INFARCTION; HUMAN; HYPERTENSION; IMPOTENCE; INCIDENCE; LIFESTYLE; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SOCIAL ASPECT; STROKE;

EID: 4644301834     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.9.735     Document Type: Review

References (41)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206.
2. Douglas JG, Bakris GL, Epstein M, et al. The Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163:525-541.
3. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 290:2560-2572.
4. Norris KC, Francis CK. Gender and ethnic differences and considerations in cardiovascular risk assessment and prevention in African Americans. In: Wong N, Gardin JM, Black HR, Practical Strategies in Preventing Heart Disease. New York: McGraw-Hill, 2000:459-484.
5. Heart Disease and Stroke Statistical Update: 2003 Update. Dallas: American Heart Association.
6. Keppel KG, Pearcy JN, Wagener DK. Trends in racial and ethnic-specific rates for the health status indicators: United States, 1990-98. Healthy People 2000 Stat Notes 2002; 23:1-16.
7. Cooper R, Cutler J, Desvigne-Nickens P et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000; 102:3137-3147.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
10. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
11. Merck reports additional subgroup analyses from LIFE study with investigational use of Cozaar; results suggest effect of Cozaar different in black patient subpopulation in study (press release). Whitehouse Station, NJ: Merck & Co., Inc. April 11, 2002.
12. Gorelick PB, Richardson D, Kelly M, et al. African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289:2947-2957.
13. Agodoa LY, Appel L, Bakris GL, et al. The African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285:2719-2728.
14. Wright JT Jr, Bakris G, Greene T, et al. The African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-2431.
15. Hall WD, Clark LT, Wenger NK, et al. The metabolic syndrome in African Americans: a review. Ethn Dis 2003; 13:414-428.
16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
17. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-1297.
18. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
19. Knight EL, Kramer HM, Curhan GC. High-normal blood pressure and microalbuminuria. Am J Kidney Dis 2003; 41:588-595.
20. East MA, Jollis JG, Nelson CL, et al. The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: do race and gender matter? J Am Coll Cardiol 2003; 41:949-954.
21. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340:609-616.
22. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344:1351-1357.
23. Yancy CW, Fowler MB, Colucci WS, et al. The US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344:1358-1365.
24. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA 2003; 289:2517-2524.
25. Howard G, Howard VJ. Reasons for Geographic And Racial Differences in Stroke (REGARDS) Investigators. Ethnic disparities in stroke: the scope of the problem. Ethn Dis 2001; 11:761-768.
26. US Renal Data System. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003.
27. Martins D, Tareen N, Norris KC. The epidemiology of end-stage renal disease among African Americans. Am J Med Science 2002; 323:65-71.
28. Jafar TH, Stark K, Schmid CH, et al. The AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244-252.
29. Wright JT Jr, Agodoa L. Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162:1636-1643.
30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
31. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349:1857-1863.
32. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2002; 355:253-259.
33. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
34. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
35. Barrier PA, Li JT, Jensen NM. Two words to improve physician-patient communication: what else? Mayo Clin Proc 2003; 78:211-214.
36. Sacks FM, Svetkey LP, Vollmer WM, et al. The DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344:3-10.
37. Appel LJ. Lifestyle modification as a means to prevent and treat high blood pressure. J Am Soc Nephrol 2003; 14(suppl 2):S99-S102.
38. Vollmer WM, Sacks FM, Svetkey LP. New insights into the effects on blood pressure of diets low in salt and high in fruits and vegetables and low-fat dairy products. Curr Control Trials Cardiovasc Med 2001; 2:71-74.
39. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413-420.
40. Smedley BD, Stith AY, Nelson AR. Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington D.C.: National Academy Press, 2002.
41. Jha AK, Varosy PD, Kanaya AM, et al. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation 2003; 108:1089-1094.